

Patent Docket P1974R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Baldwin et al.

Serial No.: 10/658,482

Filed: September 9, 2003

For:

NOVEL COMPOSITIONS AND

METHODS FOR THE TREATMENT OF

IMMUNE RELATED DISEASES

Group Art Unit: 1645

Examiner: Not Yet Assigned

Confirmation No: 3368

CUSTOMER NO: 09157

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

22313-1450 on

December 12, 2003

Tom Marrs

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

[X]37 CFR §1.97(b)

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); or
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR§ 1.491, or
- before the mailing of the first Office action on the merits; or
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

37 CFR §1.97(c)

by the applicant after the period specified in 37 CFR § 1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of Serial No.: 10/658,482 Filed: September 9, 2003

allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.

[] 37 CFR §1.97(d)

• after the period specified in CFR § 1.97(c), and is accompanied by the fee set forth in 37 CFR § 1.17(p) and a statement as specified in 37 CFR § 1.97(e), as checked below.

[If either of boxes 37 CFR § 1.97(c) or 37 CFR § 1.97(d) is checked above, the following statement under 37 CFR § 1.97(e) may need to be completed.]

- [] 37 CFR §1.97(e) Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- [] 37 CFR §1.704(d) Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- [] The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified). A copy of the items on PTO-1449 is supplied herewith.

A concise explanation of relevance of the items listed on PTO-1449 is: [X] not given

- [] given for each listed item
- given for only non-English language listed item(s) [Required]

Serial No.: 10/658,482

Filed: September 9, 2003

Page 3

[] in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR § 1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR § 1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630.

Respectfully submitted

GENENTECH, INC

Date: December 12, 2003

David A. Carpenter, Ph.D.

Reg. No. 45,945

Telephone No. (650) 225-3733

Sheet	1	Λf	1
Jueet		U	_

FORM PTO-1449 DEC 1 5 2003		3 👸	U.S. Dept. of Commerce		Atty Docket No.			Serial No.				
			Patent and Trademark Office	P197	P1974R1			10/658482				
LIST	OF DIS	CLOSURES CHARRIES	6 5	r atent and trademark Office	Appli	cant win et al.						
(Use several sheets if necessary)					"	Filing Date 09 Sep 2003			Group 1645			
	-			U.S. PATENT DOCUMENTS								
Examiner]					
Initials	1	Document Number 5, 364, 934	Date 15.11.94	Name Drayna et al.		Class		lass	Filing Date			
لـــــا	1			FOREIGN PATENT DOCUMEN	ITS		<u> </u>	J				
Examiner Initials		Document Number	Date	Country				Transla Yes	tion No			
		WO01/75166	11.10.01	PCT			0000	1400	 -T			
		·	OTHER DISCL	OSURES (Including Author, Title, Dat	te, Pertine	nt Pages, etc	.)	1				
	3	Bolton, C., "Rece (EAE) and the Imp	nt Advances in	the Pharmacological Control o Multiple Sclerosis Treatment."	f Experi	mental Alle	rgic	Encep 43-14	halomyel 9 (1995)	itis		
	4	Coligan et al, eds., "Proliferative Assays for T Cell Function" <u>Current Protocols in Immunology</u> , John Wiley & Sons, Inc., Chapter 3.12, Vol. 1 (1991)										
		Coligan et al., eds., "Delayed-Type Hypersensitivity." <u>Current Protocols in Immunology.</u> , New York: John Wiley & Sons, Inc., Chapter 4.5, (1994)										
	6	and Very Late Act Joints and Improv	ivation Antiger es Clinical Dis	Established Adjuvant Arthritis n-4 Integrins Suppresses Neutro sease." Immunology. 88:569-576	ophil and (1996)	1 T-Lymphod	yte M	ligrat:	ion to t	he		
		Nickoloff et al., "Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model" Am. J. Path. 146(3):580-588 (1995)										
										١		
			> : 3 · 7									
Examiner					Date Cons	idered						
*Examine	er: Initia	al if reference conside	red, whether or no	t citation is in conformance with MPEI	P 609; dra	w line through	h citati	on				